Garadacimab
Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa) . Garadacimab has the potential for hereditary angioedema research[1].
Product Specifications
CAS Number
2162134-62-3
Product Name Alternative
CSL312
UNSPSC
12352203
Target
Factor Xa
Type
Inhibitory Antibodies
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/garadacimab.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Garadacimab]
Molecular Weight
(146.5 kDa)
References & Citations
[1]Dipti Pawaskar, et al. Pharmacokinetic/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312) . Clin Transl Sci. 2022 Mar;15 (3) :709-720. |[2]Helen Cao, et al. Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation. J Allergy Clin Immunol. 2018 Oct;142 (4) :1355-1358.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 4
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TP303323 20 µg
TGN46 (TGOLN2) (NM_006464) Human Recombinant Protein
Sign In for Pricing
View Details 
BNCB2641-100 1x 100 µL
Prolactin (Pituitary Tumor Marker) (PRL/2641), Biotin conjugate, 0.1mg/mL
Sign In for Pricing
View Details